1 unchanged sentence
Rule 10b5-1 Plan and Non-Rule 10b5-1 Trading Arrangement Adoptions, Terminations, and Modifications
−Removed: During the three months ended June 30, 2024, none of our directors or “officers” (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of SEC Regulation S-K.
+Added: During the three months ended September 30, 2024, none of our directors or “officers” (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of SEC Regulation S-K.
The following exhibits are being filed or furnished with this quarterly report on Form 10-Q:
1 unchanged sentence
Notice of Articles of DiaMedica Therapeutics Inc.
−Removed: dated May 31, 2019
−Removed: Incorporated by reference to Exhibit 3.1 to DiaMedica’s Current Report on Form 8-K as filed with the Securities and Exchange Commission on June 4, 2019 (File No.
+Added: dated June 16, 2023
+Added: Filed herewith
Amended and Restated Articles of DiaMedica Therapeutics Inc.
1 unchanged sentence
Incorporated by reference to Exhibit 3.1 to DiaMedica’s Current Report on Form 8-K as filed with the Securities and Exchange Commission on May 18, 2023 (File No.
−Removed: Registration Rights Agreement dated as of June 28, 2024 among DiaMedica Therapeutics Inc.
−Removed: and the Purchasers Party Thereto
−Removed: Incorporated by reference to Exhibit 4.4 to DiaMedica’s Registration Statement on Form S-3 as filed with the Securities and Exchange Commission on July 10, 2024 (File No.
−Removed: Form of Securities Purchase Agreement dated as of June 25, 2024 by and among DiaMedica Therapeutics Inc.
−Removed: and the Purchasers Party Thereto
−Removed: Incorporated by reference to Exhibit 10.1 to DiaMedica’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 25, 2024 (File No.
−Removed: DiaMedica Therapeutics Inc.
−Removed: Amended and Restated Omnibus Incentive Plan (Effective May 22, 2024)
−Removed: Incorporated by reference to Exhibit 10.1 to DiaMedica’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 23, 2024 (File No.
Certification of Chief Executive Officer Pursuant to Exchange Act Rules 13a-14(a)/15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
9 unchanged sentences
Financial statements from the quarterly report on Form 10-Q of DiaMedica Therapeutics Inc.
−Removed: for the three and six months ended June 30, 2024, formatted in Inline XBRL:
+Added: for the three and nine months ended September 30, 2024, formatted in Inline XBRL:
(i) the Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations and Comprehensive Loss, (iii) Condensed Consolidated Statements of Shareholders’ Equity, (iv) Condensed Consolidated Statements of Cash Flows, and (v) Notes to the Condensed Consolidated Financial Statements.
4 unchanged sentences
DIAMEDICA THERAPEUTICS INC.
−Removed: August 7, 2024
+Added: November 13, 2024
/s/ Rick Pauls
1 unchanged sentence
(Principal Executive Officer)
−Removed: August 7, 2024
+Added: November 13, 2024
/s/ Scott Kellen
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.